Status:
UNKNOWN
LEC Proliferation in Vivo and In-vitro
Lead Sponsor:
Prim. Prof. Dr. Oliver Findl, MBA
Conditions:
Posterior Capsule Opacification
Eligibility:
All Genders
21-105 years
Brief Summary
Investigate the proliferative capacity of individual lens epithelium capsule specimens in vitro and correlate it to the risk of developing PCO
Detailed Description
Cataract, the clouding of the eye's lens, is still the leading cause of blindness worldwide. Until now surgery is the only therapy available for the disease. Cataract surgery is nowadays considered a ...
Eligibility Criteria
Inclusion
- Age-related cataract.
- Patients in the age group of 21 years and older.
- Patients with uncomplicated cataract.
- Patients without any relevant systemic or ocular morbidity.
- Patients with well dilating pupils.
- Written informed consent prior to any study specific action.
Exclusion
- Patients with complicated cataract.
- Patients with big differences in LOCS scale between the two eyes.
- Patients having corneal pathology.
- Patients with any form of ocular inflammation.
- Patients with glaucoma, retinal pathologies.
- Patients with traumatic cataracts, subluxated and dislocated lens, prior h/o ocular surgery, pseudoexfoliation.
- Any intraoperative complications like posterior capsule rupture.
- In case of pregnancy (pregnancy test will be taken preoperatively in women of reproductive age).
Key Trial Info
Start Date :
January 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2021
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03857685
Start Date
January 1 2019
End Date
January 1 2021
Last Update
March 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vienna Institute for Research in Ocular Surgery (VIROS)
Vienna, Austria, 1140